Home World News Vepdegestrant Prolongs PFS in a Subgroup of Patients with ER-positive, HER2-negative Advanced... World News Vepdegestrant Prolongs PFS in a Subgroup of Patients with ER-positive, HER2-negative Advanced Breast Cancer with ESR1 mutations By Ogkologos - June 30, 2025 849 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the VERITAC-2 study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR Combination immunotherapy for advanced bowel cancer approved for NHS in England June 16, 2021 Trastuzumab Deruxtecan Shows Promising Activity Among Patients with HER2-positive and Signal... September 2, 2024 How I Rebuilt My Self-Image After a Laryngectomy: A Cancer Survivor’s... April 20, 2023 For Children with Neuroblastoma, Trial Results Highlight Continued Evolution of Treatment September 23, 2019 Load more HOT NEWS How to Talk to Your Kids About Ways to Prevent Cancer EMA Recommends to Extend Therapeutic Indications for Crizotinib in Paediatric Patients Genetic Signature May Help Tailor Treatment for Meningioma Evaluating Targeted Therapy for People With Advanced Gastric or Gastroesophageal Junction...
